Alpha Teknova (NASDAQ:TKNO) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Alpha Teknova's stock has been given a Sell (D-) rating by Weiss Ratings, despite a recent upgrade to a strong-buy rating from Stephens.
• The stock currently has a market cap of $284.16 million with a current price of $5.31, significantly lower than its 12-month high of $10.37.
• Recent earnings reports show Alpha Teknova beating expectations with $10.29 million in revenue, while forecasting a loss of -0.58 earnings per share for the current fiscal year.

Alpha Teknova (NASDAQ:TKNO - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Stephens upgraded shares of Alpha Teknova to a "strong-buy" rating and set a $8.00 price objective for the company in a research report on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.00.

Alpha Teknova Price Performance

NASDAQ:TKNO traded up $0.07 during trading hours on Wednesday, reaching $5.31. 156,028 shares of the company were exchanged, compared to its average volume of 351,352. The company has a current ratio of 5.87, a quick ratio of 4.70 and a debt-to-equity ratio of 0.17. The stock's 50-day moving average is $4.76 and its 200-day moving average is $5.31. The firm has a market cap of $284.16 million, a PE ratio of -12.64 and a beta of 0.41. Alpha Teknova has a twelve month low of $3.94 and a twelve month high of $10.37.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. The company had revenue of $10.29 million during the quarter, compared to analysts' expectations of $9.90 million. Alpha Teknova had a negative net margin of 55.24% and a negative return on equity of 26.51%. Alpha Teknova has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Alpha Teknova will post -0.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP lifted its stake in Alpha Teknova by 46.2% in the fourth quarter. Two Sigma Investments LP now owns 15,148 shares of the company's stock worth $126,000 after acquiring an additional 4,789 shares during the last quarter. Kestra Private Wealth Services LLC raised its holdings in Alpha Teknova by 94.3% during the first quarter. Kestra Private Wealth Services LLC now owns 59,953 shares of the company's stock worth $311,000 after purchasing an additional 29,105 shares in the last quarter. Tradewinds LLC. raised its holdings in Alpha Teknova by 205.6% during the first quarter. Tradewinds LLC. now owns 133,088 shares of the company's stock worth $691,000 after purchasing an additional 89,538 shares in the last quarter. CenterBook Partners LP acquired a new stake in Alpha Teknova during the first quarter worth approximately $1,581,000. Finally, Alpine Global Management LLC acquired a new stake in Alpha Teknova during the first quarter worth approximately $128,000. Hedge funds and other institutional investors own 13.81% of the company's stock.

About Alpha Teknova

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.